Carvone Attenuates Irinotecan-Induced Intestinal Mucositis and Diarrhea in Mice

Ban W. Abbas *1 and Sarmed H. Kathem **

* Ministry of Health and Environment, Medical City Health Directorate, Baghdad, Iraq.
** College of Pharmacy, University of Baghdad, Pharmacology and Toxicology department

Abstract

Intestinal mucositis is referring to inflammatory or ulcerative lesions of the oral or gastrointestinal tract; one of the main reasons is treatment with cancer chemotherapy. The prodrug Irinotecan is converted by carboxylesterase to the active metabolite SN-38, conjugated by UGT enzyme to SN-38G and then deconjugated by β-glucoronidase produced by intestinal bacterial flora to produce SN-38. Irinotecan induces intestinal mucositis and diarrhea due to increased concentration of its active metabolite (SN-38). To evaluate the protective effect of carvone, I.P injection of (75mg/kg/day) of irinotecan for 4 days to induce intestinal mucositis, carvone administered to mice orally for 6 days starting from day 1. Results showed that carvone (50mg/Kg and 100mg/Kg) significantly and by dose-dependent manner attenuated body weight loss (9.39±1.56 % vs. -23.21±1.65 %), diarrhea scores (0.50±0.244 vs. 2.67±0.211) and serum TNF-α level (1361.44±55.075 vs. 3402.12±321.56 ng/ml) compared to experimental model group. In conclusion, carvone exerted a dose dependent anti-inflammatory and protective effect by attenuation irinotecan-induced intestinal mucositis.

Keywords: Intestinal mucositis, Irinotecan, Carvone, Body weight variation, Diarrhea score, TNF-α level.

Introduction

Mucositis is an inflammatory or ulcerative lesions of the oral or gastrointestinal tract. Infectious disease, immune deficiency and Medications as well as high-dose cancer therapy could be considered as one of main causative factors for mucositis (1). The condition was developed by breakdown of the mucosal barrier leading to: significant ulceration of the oral cavity and GIT leading to passing of bacteria into the systemic circulation, increasing the risk of infections, an imbalance between secretion and absorption, demonstrated as diarrhea (2). Chemotherapy induced diarrhea (CID) being a principal reason for pain and reduced quality of life during cancer treatment because it is one of the most debilitating adverse effects of chemotherapy (3). The progression of mucositis can be divided into five phases: initialization, activation, signal amplification, ulceration and Healing phase (4). Severe diarrhea leading to dehydration, renal insufficiency, malnutrition, fever, neutropenia, infectious complications, or serious electrolyte imbalances can result in hospitalization (5). The presence of CID can impact on providers to modulate chemotherapeutic agents, decrease treatment doses, delay therapy, or even cease therapy, resulting in potentially worsened clinical outcomes (5). Irinotecan hydrochloride is a prodrug that is metabolically activated to 7-ethyl10-hydroxycamptothecin (SN-38) by carboxylesterase 2 in the blood and liver, and thereafter SN-38 is conjugated in the liver by uridine diphosphate glucuronosyl transferase 1A1 to produce a β-glucuronide conjugate, SN-38G (6).
Irinotecan and SN-38 are a potent inhibitor of DNA topoisomerase I. A fundamental enzyme that controls DNA structural alterations by relaxing DNA supercoil as well as relegating cleaved DNA strands throughout DNA transcription and replication (6). Two types of diarrhea induced by irinotecan can be distinguished: early and late-onset diarrhea. Early-onset diarrhea begin during, or immediately after, drug infusion and is occur due to increased cholinergic activity, which triggers intestinal contractility and diminish the absorptive capacity of the mucosa (7). Late-onset diarrhea appear approximately 8–10 days after irinotecan infusion and is recognized by a more severe course, which is probably occur due to damage of the intestinal mucosa as a result of increased oxidative stress by biliary-secreted or intestinally deconjugated SN-38 (8). The treatment of CID involves non pharmacologic and pharmacologic interventions to inhibit diarrhea and careful serial estimation to abolish significant volume depletion or comorbidities that would need particular intervention or hospitalization (9). Anti-diarrheal therapies used are: Opioid, Octreotide, Budesonide, Intestinal Alkalization, Alteration of Intestinal Micro flora [Prebiotic and Probiotic, Antibiotics], D-saccharic Acid 1,4-Lactone (SAL) and Glutamine. Different plants extract found to have a protective effect against irinotecan-induced intestinal mucositis and diarrhea, as Kampo Kampo (Japanese Chinese herbal) and Mentha spicata L. (spearmint) the plant that we will study its assumed protective effect against CID. The main components of mentha spicata oil were carvone (40.8% ± 1.23%) and limonene (20.8% ± 1.12%), followed by 1,8-cineole (17.0% ± 0.60%), β-pinene (2.2% ± 0.25%), cis-dihydrocarvone (1.9% ± 0.49%), and dihydrocarveol (1.7% ± 0.31%) (10). In term of biological uses, mentha spicata used as antispasmodics and anti-platelets and insecticides (11).

Carvone (p-metha-6, 8-dien- 2-one) is a chiral monoterpeno ketone that can be achieved by distillation. It occurs naturally in two enantiomer forms: 1. S (+)-carvone (the major component in the essential oil of caraway [Carum carvi]. 2. R(-)-carvone (which is existing in the essential oil of spearmint [Mentha spicata] (12). R(-)-Carvone gives ant nociceptive activity (13). Both R(-)-carvone and (S)-(+)carvone decreased peripheral nerve activity, likely through the blockade of voltage-gated sodium channels (12). Carvone has an obvious role as it has been reported to exert anticancer effect (14), it was manifests various possible biological activities namely antioxidant, antimicrobial, nematicidal and antidiabetic effect.

**Materials and Methods**

**Chemicals and drugs**

Irinotecan vial (100mg/5ml) was purchased from Kocak pharma, Turkey. R(-) carvone was purchased from Sigma, USA. TNF-α ELISA kit purchased from Shanghai, China.

**Preparation of stock solution of carvone**

A stock solution of carvone was prepared by dissolving 0.2 ml of carvone in 10 ml of corn oil then the solution is mixed by vortex to obtain a final concentration of (1.5 mg/0.1 ml) according to the carvone dose for mice (50mg/Kg) (10). Another stock solution of carvone was prepared by dissolving 0.4 ml of carvone in 10 ml of corn oil then the solution is mixed by vortex to obtain a final concentration of (3 mg/0.1 ml) according to the carvone dose for mice (100mg/kg) (10).

**Experimental protocol**

Twenty -four albino female mice weighing (25-50 g) were brought from Animal House of College of Pharmacy, Baghdad University. Animals were maintained on standard conditions of temperature, humidity, and light /dark cycle. They had free access to standard diet and water. Mice were divided into 4 groups, each group with 6 mice as following and illustrated in figure 1:

**Group I**: six animals received a single oral daily dose of 0.1ml of normal saline for 7 successive days starting day 1. This group served as a normal control group.

**Group II**: six animals received a single dose of intraperitoneal irinotecan (75mg/kg) for 4 successive days starting day 1. This group served as a model control group.

**Group III**: six animals received a single dose of intraperitoneal irinotecan (75mg/kg) for 4 successive days starting day 1 with 0.1ml of carvone dose of 50mg/kg by oral gavage for 6 successive days starting day 1.

**Group IV**: six animals received a single dose of intraperitoneal irinotecan (75mg/kg) for 4 successive days starting day 1 with 0.1ml of carvone of dose 100mg/kg by oral gavage for 6 successive days starting day 1.

Administration of carvone done by oral gavage at 8AM and 8PM daily from day 1 through day 6. Euthinazation has done on day 7 by diethyl ether followed by cervical dislocation.
Figure 1. Schematic representation of the experimental model design.

**Serum collection:** On day 7, about 0.5ml of blood was drawn from retro-orbital area and collected in eppendorf tube and let to completely coagulated, then centrifuged for 15 min. at 5000 rpm in a cold centrifuge at 4 °C. The serum was then collected and froze for later use to measure TNF-α.

**Body weight measurement**
Mice body weights were recorded at 8AM daily. Weight values were expressed as a percentage of weight variation in relation to the baseline weight (17).

\[
\text{Weight variation (\%)} = \frac{(W2 - W1)}{W1} * 100
\]

W1= Baseline mouse weight
W2 = weight of mouse during the study period.

**Diarrhea score measurement**
The diarrhea scores were estimated daily starting 24 hr. after the last irinotecan dose between day 5 and 7. The intensity of delayed-onset diarrhea was recorded at 8:00 AM daily after the last irinotecan dose till euthanization (figure 1). Diarrhea was estimated using standard reference scale (18), as shown in table 1.

<table>
<thead>
<tr>
<th>Extent of diarrhea</th>
<th>Manifestations</th>
<th>score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>Normal stool or absent</td>
<td>0</td>
</tr>
<tr>
<td>Slight</td>
<td>Slightly wet and soft stool</td>
<td>1</td>
</tr>
<tr>
<td>Moderate</td>
<td>Wet and unformed stool with moderate perianal staining of the coat</td>
<td>2</td>
</tr>
<tr>
<td>Severe</td>
<td>Watery stool with severe perianal staining of the coat</td>
<td>3</td>
</tr>
</tbody>
</table>

**Determination of Serum TNF-α Level**
The principle of TNFα determination in serum is based on enzyme-linked immunosorbent assay (ELISA) that was use the sandwich- ELISA technique. The micro ELISA plate has been pre-coated with antibody specific to mouse TNFα(19).

**Statistical analysis**
Values expressed as mean± standard error mean (SEM). Mice body weight values presented as weight variation percent ±SEM. All statistical analyses were carried out using the statistical package of social science (SPSS) software version 25. Differences were considered significant at P<0.05. Intergroup comparisons were made by Student's t-test.

**Results**

**Effect of carvone on serum TNF-α level**
The data presented in table 2 and figure 2 showed that administration of irinotecan in the model control group (group II) resulted in a significant increase in inflammation (P<0.05) compared to the normal control group (group I) resulted in TNF- α serum levels elevation from 858.7±47.79pg/dL to 3402.12 ± 321.56pg/dL respectively. Administration of Carvone 50mg/Kg (group III), and carvone 100mg/Kg (group IV), produce a significant (P<0.05) reduction in serum TNFα levels (2210.48± 188.29pg/dL, 1361.45 ± 55.07pg/dL) respectively compared to model group (group II, 3402.12 ± 321.56pg/dL) as shown in table 2 and figure 2. This interesting result indicates a dose-dependent anti-inflammatory effect of carvone and a counteracting role in irinotecan-induced mucositis.

**Table 2. Effects of carvone on serum TNFα level in irinotecan-induce intestinal mucositis in mice**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Type of treatment</th>
<th>TNF α (pg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Normal saline</td>
<td>858.7±47.79</td>
</tr>
<tr>
<td>II</td>
<td>Irinotecan</td>
<td>3402.12±321.56 *</td>
</tr>
<tr>
<td>III</td>
<td>Carvone 50mg/kg + irinotecan</td>
<td>2210.48±188.29 *</td>
</tr>
<tr>
<td>IV</td>
<td>Carvone 100mg/kg + irinotecan</td>
<td>1361.44±55.075 *</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± standard error of means (SEM).

(*) Significantly different (P<0.05).
Figure 2. Effect of carvone on serum TNF-α level in irinotecan-induced intestinal mucositis. (*) denotes significant difference ($P<0.05$) compared with experimental model group (group II).

Effect of carvone on mice body weight

Analysis of mice weight variation percent revealed that significant ($P<0.05$) weight loss started from Day 2 in all groups except non-treated control group (Figure 3). Mice received irinotecan only (group II) showed significant ($P<0.05$) weight loss from Day 2 till euthanization. On day 7, a maximum weight loss variation percent recorded of (-23.21±1.65%). On the other hand, treatment with carvone (50mg/Kg) significant ($P<0.05$) attenuated weight loss compared to model group on day 7, where the weight variation percent calculated was (-13.78±1.62%). Furthermore by increasing the dose, treatment with carvone (100mg/Kg) significantly ($P<0.05$) hampered weight loss on days 5, 6 and 7 compared to experimental model. Interestingly, on day 7 the weight variation percent calculated was (-9.39±1.56%). Analysis of the data of weight variation percent clearly revealed that carvone exerted a dose-dependent attenuation of weight loss induced by irinotecan (Figure 3).

Figure 3. Effect of carvone treatment on mice body weight variation in irinotecan-induced intestinal mucositis and diarrhea. (*) denotes significant difference ($P<0.05$) compared with experimental model group (group II).

Effect of carvone on diarrhea score

Data obtained from the present study showed that diarrhea scores began to rise on day 5 in the model control group (group II) and other treatment groups 24 hours after the last irinotecan injection as shown in table 4. On day 7, mice in model control group (group II) suffered from severe diarrhea as manifested from the significant ($P<0.05$) high diarrhea score (2.67±0.211) compared to the normal control group (0). However, treatment with carvone (50mg/kg) resulted in significant ($P<0.05$) attenuation of the diarrhea scores (1.00±0.258) compared to model group. Increasing the dose of carvone to (100mg/kg) resulted in significant ($P<0.05$) and more reduction in diarrhea scores (0.05±0.244) compared to model group.
Mucositis is referring to inflammatory or ulcerative lesions of the oral or gastrointestinal tract\(^1\). Not only it is associated with an adverse symptoms which include pain, vomiting and diarrhea but it may limit patients’ ability to tolerate treatment if not adequately prevented and managed\(^{20}\). Chemotherapy-induced mucositis being a principal reason for pain and reduced quality of life during cancer treatment \(^3\). Irinotecan induce intestinal mucositis and late onset diarrhea. The pathogenesis of this toxic side effect is that irinotecan and its active metabolite, SN-38, can cause direct damage to the intestinal mucosal cells, leading to DNA damage and generation of reactive oxygen species due to oxidative stress \(^4\). Furthermore irinotecan can stimulate several signaling pathways, such as the (NF)-κB, increase the level of the inflammatory markers such as tumor necrosis factor (TNFα) and interleukin (IL)-1β and elevate the expression of inflammation related factor such as prostaglandin E\(_2\) (PGE\(_2\)) \(^{21}\).

In the present study, results showed a significant increase in TNFα serum level in mice confirmed irinotecan-induced intestinal mucositis mediated by inflammation, a previous study by Odilia Antunes Fernandes, Simone. 2018 confirmed that TNFα plays a crucial role in mucositis\(^{22}\), moreover, this study showed significant decrease in mice body weight with increase in diarrhea score. This result confirmed by other study and explained by lowering in intestinal absorptive capacity lead to diarrheal episodes, fluid loss and body weight loss\(^{23}\).

TNFα serum level results showed significant decrease during the use of carvone at dose 100mg/kg rather than the other dose of carvone (50mg/kg), this effect may be due to increasing the dose, carvone has antioxidant and anti-inflammatory effect \(^{24}\) leading to scavenging of ROS, decrease oxidative stress, inhibition of pro-inflammatory cytokines and decrease inflammation. The successful reduction in serum TNFα in mice treated with carvone confirmed by significant reduction in mice body weight loss and diarrhea score, weight loss occur due to diarrhea and decreased food intake, carvone has antioxidant and anti-inflammatory effect leading to reduction in inflammation, mucositis and diarrhea. In addition to its antispasmodic effect \(^{25}\) which leads to improvement of food intake and decrease diarrhea.

**Conclusion**

The present study results conclude that carvone exerted a dose dependent anti-inflammatory and protective effect by attenuation irinotecan-induced intestinal mucositis. Through reduction of inflammatory marker TNF-α and other observed parameters including weight loss and reduced diarrhea scores.

**References**


---

**Table 4. Effect of carvone treatment on diarrhea score in irinotecan-induced intestinal mucositis.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment groups</th>
<th>Diarrhea score (Mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>D4</td>
</tr>
<tr>
<td>I</td>
<td>Normal saline</td>
<td>0</td>
</tr>
<tr>
<td>II</td>
<td>Irinotecan</td>
<td>0</td>
</tr>
<tr>
<td>III</td>
<td>Carvone 50mg/kg+irinotecan</td>
<td>0</td>
</tr>
<tr>
<td>IV</td>
<td>Carvone 100mg/kg+irinotecan</td>
<td>0</td>
</tr>
</tbody>
</table>

(*)**: significant difference (P< 0.05).

(\(D\)): days of treatment.


